[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530537":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":31,"locations":38,"responsibleParty":52,"collaborators":54,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":10,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Northumbria Healthcare NHS Foundation Trust","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with severe exacerbation of COPD and eosinophils \u003C 0.05 x 10^9\u002FL",null,"Participants to be included in the co-primary outcomes for the time to recovery from eosinopenia analysis as well as the analysis to identify independent factors associated with eosinopenia on admission in patients with a severe exacerbation of COPD. This group of participants will also be included in all secondary outcomes.",[13],"Diagnostic Test: Blood eosinophil count",{"label":15,"type":10,"description":16,"interventionNames":17},"Participants with severe exacerbation of COPD and eosinophils >= 0.05 x 10^9\u002FL","Participants will be included in the co-primary outcome to identify independent factors associated with eosinopenia on admission in patients with a severe exacerbation of COPD. This group of participants will also be included in some of the secondary outcomes.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Blood eosinophil count","To determine the time it takes for blood eosinophil count to recover to baseline stable state following severe exacerbation of COPD associated with admission eosinopenia and to explore independent factors associated with admission eosinopenia.",[9,15],[25,28],{"name":26,"affiliation":5,"role":27},"Stephen Bourke, MBChB, PhD","STUDY_CHAIR",{"name":29,"affiliation":5,"role":30},"Peter Ireland, MBBS","PRINCIPAL_INVESTIGATOR",[32,36],{"name":26,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","0191 293 4351","stephen.bourke@nhct.nhs.uk",{"name":29,"role":33,"phone":10,"phoneExt":10,"email":37},"peter.ireland@northumbria-healthcare.nhs.uk",[39],{"facility":5,"status":40,"city":41,"state":10,"zip":10,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","North Shields","United Kingdom","UK",{"type":45,"coordinates":46},"Point",[47,48],-1.44925,55.01646,{"lat":48,"lon":47},[51],{"name":29,"role":33,"phone":10,"phoneExt":10,"email":37},{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[55,57,60],{"name":56,"class":6},"Newcastle University",{"name":58,"class":59},"Chiesi UK","INDUSTRY",{"name":61,"class":59},"GlaxoSmithKline","100530537","eosinopenia-in-severe-copd-exacerbation-100530537",false,"NCT06188065","Eosinopenia in Severe COPD Exacerbation","Associates of, and Time to Recovery From, Eosinopenia in Severe COPD Exacerbation","A-TREC","Inclusion Criteria:\n\n* Admitted to hospital with primary clinical diagnosis of exacerbation of COPD\\*\n* Smoking history of at least 10 pack years\n* Airflow obstruction: FEV1\u002FFVC ratio \\\u003C 0.7 confirmed on historic or inpatient spirometry\n* Capacity to give informed consent to participate\n\nExclusion Criteria:\n\n* Parasitic infection, systemic fungal infection (excluding infection limited to nails or skin), eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome or other conditions associated with a high eosinophil count#\n* Active malignancy\n* Maintenance oral prednisolone or other systemic steroids, anti-interleukin 5 therapy or other medication known to influence eosinophils\n* Patients with poor venous access\n* Investigator confirmed history of asthma\n* Non-COPD related health problems which in the view of the primary investigator may compromise the conduct and completion of the study\n\nADDITIONAL CRITERIA FOR THE TIME TO RECOVERY FROM EOSINOPENIA ANALYSIS ONLY\n\nInclusion criteria:\n\n* Eosinopenia on admission\n* Uneventful recovery\\*\n\n  * Eosinopenia on admission who do not receive a further course of systemic corticosteroids or require emergency hospital admission for an acute illness in the six weeks following admission to hospital with a severe exacerbation of COPD.","ALL","35 Years",{"count":73,"type":74},200,"ESTIMATED","OBSERVATIONAL","The goals of this observational study are to identify factors independently associated with admission eosinopenia in patients with a severe exacerbation of chronic obstructive pulmonary disease (COPD) and to determine when blood eosinophil count (BEC) will recover to baseline stable state in patients who are admitted to hospital with a severe exacerbation of COPD and associated eosinopenia.\n\nThe main aims of the study are to:\n\n1. Identify demographic, physiological and clinical factors independently associated with admission eosinopenia in patients with a severe exacerbation of COPD\n2. Assess the time to recovery from eosinopenia to stable BEC following a severe exacerbation of COPD",[78],"Chronic Obstructive Pulmonary Disease","2026-04-13",{"date":81,"type":82},"2026-04-14","ACTUAL",{"date":84,"type":82},"2024-01-22",{"date":86,"type":74},"2026-07",{"name":5,"class":6},1]